| Company/Division name | Seattle Genetics |
| Type of work | Manufacturing |
| If manufacturing, is the company an OEM? | Yes |
| Reshoring category: | Kept from Offshoring |
| Year reshoring announced: | 2017 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 43.3 |
| City reshored to: | Bothell |
| State(s) reshored to: | WA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Antibodies for Cancer Treatment |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption risk/Natural disaster risk/Political instability |
| What domestic positive factors made reshoring more attractive? | Customization/Flexibility, Skilled workforce availability/training |
